Literature DB >> 9421305

Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.

J W Wegener1, I Gath, U Förstermann, H Nawrath.   

Abstract

1. The effects of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), an activator of soluble guanylyl cyclase, on tension, levels of cyclic GMP and cyclic AMP, and cardiac L-type Ca2+-current (I[Ca(L)]) were investigated in aortic smooth muscle and ventricular heart muscle from rat. 2. YC-1 (0.1-30 microM) induced a concentration-dependent relaxation in aortic rings precontracted with phenylephrine (3 microM). The relaxant effects of YC-1 were reversed by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (30 microM; ODQ), potentiated by zaprinast (10 microM) and antagonized by Rp-8-Br-cGMPS (100 microM). 3. In ventricular heart muscle strips, YC-1 (30 microM) exhibited no effects on force of contraction (Fc) in the absence or presence of either zaprinast (10 microM) or 3-isobutyl-1-methylxanthine (30 microM). Fc was slightly increased by YC-1 (30 microM) in the presence of isoprenaline (100 nM), but this effect was not influenced by ODQ (30 microM). 4. Cardiac I[Ca(L)] was not significantly affected by YC-1 (30 microM), either in the absence or presence of isoprenaline (30 nM). 5. In aortic rings, cyclic GMP levels were increased almost 3 fold by YC-1 (30 microM); this effect was abolished by ODQ (30 microM). In isolated ventricular cardiomyocytes, cyclic GMP levels were not affected by YC-1 (30 microM) but almost doubled by activation of particular guanylyl cyclase with atriopeptin II (100 nM). 6. YC-1 (30 microM) did not increase cyclic AMP levels either in aortic rings or in ventricular cardiomyocytes. In contrast, isoprenaline (3 microM) increased cyclic AMP levels about two fold in both tissues. In cardiomyocytes, the effect of isoprenaline (3 microM) was slightly enhanced by YC-1 (30 microM). 7. It is concluded that relaxation of smooth muscle preparations by YC-1 is mediated mainly by activation of soluble guanylyl cyclase and subsequent increase in cyclic GMP levels. The failure of YC-1 to affect cardiac Fc, levels of cyclic GMP, and I[Ca(L)] suggests that soluble guanylyl cyclase is not influenced by YC-1 in rat heart muscle or only barely present in this tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421305      PMCID: PMC1565096          DOI: 10.1038/sj.bjp.0701542

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

Review 1.  Isoforms of NO-sensitive guanylyl cyclase.

Authors:  Michael Russwurm; Doris Koesling
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

2.  Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

Authors:  P Wohlfart; T Malinski; H Ruetten; U Schindler; W Linz; K Schoenafinger; H Strobel; G Wiemer
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Authors:  J Galle; U Zabel; U Hübner; A Hatzelmann; B Wagner; C Wanner; H H Schmidt
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

5.  YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells.

Authors:  Ming-Shyan Chang; Wen-Sen Lee; Che-Ming Teng; Horng-Mo Lee; Joen-Rong Sheu; George Hsiao; Chien-Huang Lin
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

6.  Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Authors:  Bobby Nossaman; Edward Pankey; Philip Kadowitz
Journal:  Crit Care Res Pract       Date:  2012-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.